"Michigan Institute for Neurological Disorders (MIND) provides the most comprehensive diagnostic, therapeutic, and supportive services to adult patients and their families affected with neurological conditions. In an effort to improve outcomes and our patient’s quality of life, MIND is one of the few comprehensive private neurological facilities in the country dedicated to the betterment of our patients through the use of onsite, cutting edge neuro-diagnostic technology, neuro-imaging, infusion services and medical education, and research. If you are seeking to send us a general fax, our number is (248) 553-5957."

During the past decade, Michigan Institute for Neurological Disorders conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 5 clinical trials were completed, i.e. on average, 125% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Michigan Institute for Neurological Disorders" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Biogen" with 4 trials sponsored, "Genentech, Inc." with 3 trials sponsored, "Allergan" with 1 trials sponsored and "CENTOGENE GmbH Rostock" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Michigan Institute for Neurological Disorders" #1 collaborator was "Elan Pharmaceuticals" with 2 trials as a collaborator, "Bayer" with 1 trials as a collaborator and "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Michigan Institute for Neurological Disorders" are "Multiple Sclerosis" (6 trials), "Multiple Sclerosis, Relapsing-Remitting" (5 trials), "Multiple Sclerosis, Primary Progressive" (1 trials), "Muscle Spasticity" (1 trials) and "Parkinson´s Disease" (1 trials). Many other conditions were trialed in "Michigan Institute for Neurological Disorders" in a lesser frequency.

Most popular intervention types in "Michigan Institute for Neurological Disorders" are "Drug" (13 trials), "Biological" (2 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ocrelizumab" (6 trials), "Placebo" (5 trials), "Avonex" (2 trials), "Interferon beta-1a" (2 trials) and "Natalizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Michigan Institute for Neurological Disorders" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Michigan Institute for Neurological Disorders". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Michigan Institute for Neurological Disorders, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Michigan Institute for Neurological Disorders, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".